Coloplast A/S, the Danish medical device company specialising in intimate healthcare products, has announced that its Annual General Meeting (AGM) will be held on Tuesday, 1 December 2026 at 3:30 pm CET. The meeting will take place at the company's premises at Holtedam 3, in the Aage Louis-Hansen Auditorium, Humlebæk, Denmark. The notice of the AGM has been formally enclosed with the announcement, and an official notice document has been published alongside the company update. Investors holding or monitoring the company's B ordinary shares on the London market under ticker 0QBO may wish to review the enclosed AGM notice for agenda details.

Key Points

  • Coloplast A/S (0QBO) — Danish medical device company focused on intimate healthcare
  • AGM confirmed for Tuesday, 1 December 2026 at 3:30 pm CET at the company's Humlebæk headquarters
  • Formal notice of the AGM has been published and attached to the announcement as an official document
  • Investors should review the enclosed AGM notice for full agenda items and any shareholder resolutions

Coloplast Confirms AGM Date and Venue at Humlebæk Headquarters

Coloplast A/S has formally notified shareholders that its 2026 Annual General Meeting will be convened on 1 December 2026, beginning at 3:30 pm Central European Time. The venue is the Aage Louis-Hansen Auditorium, located at Holtedam 3, Humlebæk, Denmark — the company's registered operational base. A formal notice document, titled "Notice of Annual General Meeting 2026," has been attached to the announcement. The company notes that where any discrepancy exists between the Danish and English language versions of the announcement, the English version shall take precedence, which is a standard provision under Danish corporate governance practice.

Coloplast's Mission and Global Focus on Intimate Healthcare Products

Coloplast A/S describes its mission as making life easier for people with intimate healthcare needs, with its stated vision being to set the global standard for listening and responding to patients. The company's values framework centres on closeness, passion, respect, and responsibility. Registered in Denmark under company registration number 69749917, Coloplast operates internationally in the medical devices sector, with its products addressing areas such as ostomy care, urology, and wound care. These segments place the company within a specialised and recurring-revenue healthcare niche, which investors in the sector typically regard as resilient across economic cycles.

Investor and Media Contacts Named in the Coloplast AGM Notice

The announcement identifies Anders Lonning-Skovgaard, Executive Vice President and CFO, as the primary investor and analyst contact, reachable via the company's main switchboard. Aleksandra Dimanovska, Vice President of Investor Relations, is also named with direct contact details. For press and media enquiries, Peter Mønster, Head of Media Relations and Corporate Content, is listed as the designated contact. The provision of named senior contacts alongside an AGM notice is consistent with Coloplast's obligations under Danish and broader European disclosure frameworks for listed companies.

What Shareholders Should Review Ahead of the December 2026 Meeting

Shareholders are encouraged to consult the full attached AGM notice for details on resolutions, voting procedures, and any items proposed for consideration at the December meeting. The announcement itself does not disclose specific agenda resolutions, proposed dividend figures, or board changes, meaning investors must refer to the enclosed formal document for those details. The company did not disclose financial updates or guidance in this announcement. Those with holdings in Coloplast's B ordinary shares under the 0QBO reference on Investegate should monitor further updates from the company ahead of the December meeting date.